PAD Profile : Selegiline hydrochloride - Parkinson's disease (neuroprotective therapy)

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Selegiline hydrochloride - Parkinson's disease (neuroprotective therapy)

Keywords :

dopamine agonists, Parkinsons disease, PD, monoamine-oxidase-B inhibitors, MAOB

Brand Names Include :

Eldepryl, Zelapar

Traffic Light Status

Status :

Non Formulary

Formulations :

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

NFD1

Comments :

No comments returned.

Documents :

No guidelines returned.

Type

Document

Review Date

Guidelines (National)

Date

Committee Name

Narrative

06 June 2018

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Monoamine-oxidase-B inhibitors (rasagiline, selegiline) are not recommended as a neuroprotective therapy except in the context of a clinical trial.

04. Central Nervous System

04.09.01. Dopaminergic drugs used in parkinsonism